Mucolytic therapy in cystic fibrosis

Journal of the Royal Society of Medicine, Supplement

Volumn 94, Issue 40, 2001, Pages 17-24

  Wallis, C ^a  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AMILORIDE; DEOXYRIBONUCLEASE; GELSOLIN; MANNITOL; MESNA; SODIUM CHLORIDE; TRANSMEMBRANE CONDUCTANCE REGULATOR;

CLINICAL TRIAL; CONFERENCE PAPER; CYSTIC FIBROSIS; DRUG EFFICACY; ENZYME ACTIVITY; HUMAN; LUNG CLEARANCE; LUNG FUNCTION TEST; MUCOCILIARY CLEARANCE; MUCOLYSIS; MUCUS SECRETION; OUTCOMES RESEARCH; SPUTUM; VISCOSITY;

EID: 0034853558     PISSN: 02675331     EISSN: None     Source Type: Journal    
DOI: 10.1177/014107680109440s06     Document Type: Conference Paper

References (60)

1. Mucins in the respiratory tract
2. Role of the physiochemical properties of mucus in the protection of the respiratory epithelium
3. Non-invasive in vivo fluorescence measurement for airway surface liquid properties - Depth, salt concentration, pH and viscosity
4. Cystic fibrosis
5. Bronchospasm after inhalation of pancreatic dornase
6. Efficacy and safety of short-term administration of aerolised recombinant human DNase 1 in adults with stable stage cystic fibrosis
7. Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis
8. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis
9. DNase and other mucolytics
10. Dornase alpha for cystic fibrosis
11. DNase in cystic fibrosis: The challenge of assessing response and maximising benefit
12. The role of recombinant human DNase in the treatment of patients with cystic fibrosis: Many promises more problems
13. Increase in free IL-8 concentration and the chemotactic response of neutrophils to DNase treated cystic fibrosis sputum
14. Neutrophil proteinases and rhDNase therapy in cystic fibrosis
15. Consensus conference: Practical applications of Pulmozyme
16. Dornase alfa for cystic fibrosis. Patients should not be denied a safe, effective treatment
17. Retrospective review of the effects of rhDNase in children with cystic fibrosis
18. The clinical use of rhDNAse
19. Human recombinant DNase in cystic fibrosis
20. Aerosol delivery and safety of recombinant human deoxyribonuclease in young children with cystic fibrosis: A bronchoscopic study
21. Deoxyribonuclease for cystic fibrosis
22. A randomised comparative trial of hypertonic saline, alternate day and daily rHDNase in children with cystic fibrosis
23. A randomized, placebo-controlled trial of two years' treatment with dornase alfa (Pulmozyme) in cystic fibrosis patients aged 6-10 years with early lung disease
24. RhDNase therapy in patients with CF: Is it possible to predict lung function improvement?
25. DNase use in the daily care of cystic fibrosis: Who benefits from it and to what extent? Results of a cohort study of 199 patients in 13 centres
26. Long term effects of aerolised rhDNase on pulmonary disease progression in patients with cystic fibrosis
27. Combined effects of hypertonic saline and rhDNase on cystic fibrosis sputum in vitro
28. Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis
29. Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis
30. Nebulised hypertonic saline for cystic fibrosis
31. Tolerability of nebulised hypertonic saline in children with cystic fibrosis
32. The effect of salt water on alveolar epithelial barrier function
33. Inhaled hypertonic saline increases sputum expectoration in cystic fibrosis
34. Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis
35. Systematic review of N-acetylcysteine in cystic fibrosis
36. Sulfhydryl-mediated depression of ciliary activity: An adverse effect of acetylcysteine
37. Bronchospasm caused by acetylcysteine in children with bronchial asthma
38. A double-blind study of the use of acetylcysteine in patients with cystic fibrosis
39. Oral acetylcysteine in cystic fibrosis. A co-operative study
40. Controlled trial of oral N-acetylcysteine in cystic fibrosis
41. A double-blind placebo controlled trial with oral ambroxol and N-acetylcysteine for mucolytic treatment in cystic fibrosis
42. The clinical effect and the effect on the ciliary motility of oral N-acetylcysteine in patients with cystic fibrosis and primary ciliary dyskinesia
43. Reduction in viscoelasticity in cystic fibrosis sputum in vitro using combined treatment with nacystelyn and rhDNase
44. Randomised multicententric double blind study of tolerability and efficacy of a DPI Nacystelyn versus placebo in cystic fibrosis patients treated by rhDNase for at least 3 months
45. Sputum liquefying agents: A comparative in vitro evaluation
46. Controlled trial of intermittent aerosol therapy with sodium 2-mercaptoethane sulphonate in cystic fibrosis
47. In vitro assessment of combined antibiotic and mucolytic treatment for Pseudomonas aeruginosa infection in cystic fibrosis
48. Reduction in viscosity of cystic fibrosis sputum in vitro by gelsolin
49. Gelsolin activates DNase 1 in vitro and cystic fibrosis sputum
50. Inhalation of dry-powder mannitol increases mucociliary clearance
51. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: A pilot study
52. A pilot study of aerolised amiloride for the treatment of lung disease in cystic fibrosis
53. Acute and long term amiloride inhalation in cystic fibrosis lung disease
54. Effect of amiloride and saline on nasal mucociliary clearance and potential difference in cystic fibrosis and normal subjects
55. Hypertonic saline and recombinant human DNase: A randomised cross-over pilot study in patients with cystic fibrosis
56. In vivo use of hypertonic Saline in CF
57. Determining optimal therapy - Randomized trials in individual patients
58. Efficacy of DNase in individual children using the n-of-1 study design
59. Recombinant DNase in cystic fibrosis, a protocol for targeted introduction through n-of-1 trials
60. Randomized clinical trials in single patients during a 2-year period